Vertex Pharmaceuticals Incorpor found using ticker (VRTX) now have 20 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 300 and 224 and has a mean target at 266.6. With the stocks previous close at 227.05 this would indicate that there is a potential upside of 17.4%. The 50 day moving average now sits at 226.15 and the 200 moving average now moves to 197.13. The company has a market capitalisation of $59,276m. Visit the company website at:

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies; Moderna Therapeutics; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem; Janssen Pharmaceuticals; Merck KGaA; Kymera Therapeutics; Ribometrix; and Molecular Templates The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Source link